-
GSK (LSE:GSK) has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline.
-
The partnership with Wave Life Sciences focuses on RNA-based therapies targeting liver diseases using GalNAc-siRNA technology.
-
GSK expanded its tuberculosis research with AN2 Therapeutics, supported by new funding from the Bill & Melinda Gates Foundation for boron-based drug discovery.
-
The Wave Life Sciences hepatology move and fresh Gates-backed TB research funding matter, but investors need to look beyond this news. We have also flagged 3 warning signs for GSK.
For readers interested in more opportunities around healthcare research and new treatment platforms, the next step is exploring 7 healthcare AI stocks .
GSK operates as a global pharmaceuticals group with a focus on vaccines, specialty medicines, and broader treatments. Partnerships in RNA therapies and infectious disease research plug directly into its core expertise in developing and manufacturing new drugs for widespread use.
4 things going right for GSK that this headline doesn't cover.
How does the Wave Life Sciences deal plug into GSK's business model?
The GalNAc-siRNA hepatology candidate gives GSK another modality in liver disease where targeted RNA drugs can fit alongside vaccines and specialty medicines. It also lets GSK access Wave's SpiNA design platform without building all of that RNA chemistry capability internally, which spreads the development risk across several collaboration programs.
Does this news change the GSK Narrative or just add another data point?
These collaborations sit squarely in the existing GSK Narrative that highlights heavier R&D reinvestment and business development to support long term sales and margin expansion. The Wave and AN2 deals speak to that catalyst, while the high R&D spend and execution uncertainty flagged in the Narrative still apply if these programs move slowly or fail to produce strong late stage assets.
See how these catalysts shape GSK's path to a £21.61 fair value .
What should GSK investors watch next to test whether this read holds up?
The clearest marker will be whether GSK or Wave disclose that one of the three remaining collaboration programs reaches formal candidate selection over the next research updates, triggering further milestone payments. That would signal early follow through on the platform bet, rather than a one off hepatology win.
Add GSK to your Watchlist and get alerts as these catalysts play out.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GSK.L .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
